Oramed Pharmaceuticals Inc. Common Stock (ORMP) Stock
NASDAQ · ORMP
4.71
Fundamentals
Market cap
$196.76M
Price / Earnings ratio
1.1x
Price / Sales ratio
N/A
Price / Book ratio
0.6x
Return on assets
50.0%
Ex-Dividend date
16 Jan 2026
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
5.29%
Debt / Equity ratio
N/A
Recent news

Stocktwits
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
NeutralORMPFebruary 20, 2026
StocktwitsNeutral
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
ORMP

PennyStocks
Best Penny Stocks To Buy Today? 4 To Watch Under $5
NeutralORMPMay 4, 2023
PennyStocksNeutral
Best Penny Stocks To Buy Today? 4 To Watch Under $5
ORMP
Technicals
OscillatorsSell5 Indicators
Moving AveragesNeutral12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Stocktwits
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
NeutralORMPFebruary 20, 2026
StocktwitsNeutral
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
ORMP

PennyStocks
Best Penny Stocks To Buy Today? 4 To Watch Under $5
NeutralORMPMay 4, 2023
PennyStocksNeutral
Best Penny Stocks To Buy Today? 4 To Watch Under $5
ORMP
About Oramed Pharmaceuticals Inc. Common Stock
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
SectorHealthcare
IndustryBiotechnology
CEOMr. Nadav Kidron Esq.
IPO DateApr 21, 2006
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman | 1974 |
| Mr. Joshua Hexter | Chief Operating & Business Officer | 1970 |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director | 1940 |
| Mr. Avraham Gabay | CFO, Treasurer & Secretary | 1985 |
Fundamentals
Valuation
Market cap$196.76M
Price-to-sales ratioN/A
Price-to-book value0.63
Price-earnings ratio1.10
Return on Equity55.00%
Return on SalesN/A
Return on Assets50.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$4.23
Income Statement
Average volume231,016
EBITDA$116.61M
1 year high (52w)$5.47
1 year low (52w)$2.09
Dividend
Ex dividend date16 Jan 2026
Dividend amount$0.00
Dividend yield5.29%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesNeutral12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | -11.7 | +14.4 | -2.5 |



